Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;133(7-8):292-297.
doi: 10.1007/s00508-020-01780-0. Epub 2020 Dec 9.

Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19

Satoru Chiba  1
Affiliations

Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19

Satoru Chiba. Wien Klin Wochenschr. 2021 Apr.

Abstract

Background: Since December 2019 coronavirus disease 2019 (COVID-19) outbreaks have occurred in China and many countries around the world. The effectiveness of oseltamivir on COVID-19 suspected outpatients without hypoxia was evaluated.

Methods: A total of 16 COVID-19 suspected medical personnel and their cohabitation families without hypoxia, who came to the adult fever clinic from March to June 2020 were studied. All patients received antiviral therapy (oseltamivir) and antibacterial therapy together.

Results: Most of the infected patients were female (10, 63%), 1 had diabetes (6%) and 3 hypertension (19%). The median age was 45 years (interquartile range [IQR] 31-60 years). Oseltamivir administration made the temperature fall within 24 h in part (10, 63%). Clinical data were compared between patients receiving early treatment (ET) with oseltamivir, initiated within 24 h, and patients administered late treatment (LT), initiated after this time point. Duration of fever was shorter in the ET group than in the LT group (31 ± 21 h versus 94 ± 38 h; p < 0.001). The time from fever onset to treatment initiation correlated with duration of fever (r = 0.77; p < 0.001) and the time from peak to decline (r = 0.58; p < 0.05).

Conclusion: These findings suggest that early oseltamivir administration may lower the duration of fever in COVID-19 suspected outpatients without hypoxia when it is used in combination with antibacterial therapy.

Keywords: Antiviral agents; COVID-19; Duration of fever; Early treatment; Levofloxacin.

PubMed Disclaimer

Conflict of interest statement

S. Chiba declares that he has no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the COVID-19-suspected outpatients study cohort. SpO2 peripheral capillary oxygen saturation
Fig. 2
Fig. 2
Comparison of ET (n = 10) versus LT (n = 6). a Duration of fever, b time from onset to peak, c time from peak to decline. ET patients receiving early treatment with oseltamivir, initiated within 24 h, LT patients receiving late treatment with oseltamivir, initiated after 24 h
Fig. 3
Fig. 3
Correlation between time from fever onset to treatment initiation and duration of fever (a) or time from peak to decline (b)
See this image and copyright information in PMC

References

    1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924. doi: 10.1016/j.ijantimicag.2020.105924. - DOI - PMC - PubMed
    1. Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020;19:105948. doi: 10.1016/j.ijantimicag.2020.105948. - DOI - PMC - PubMed
    1. WHO. Director-General’s opening remarks at the media briefing on COVID-19—11 March. 2020. https://www.who.int/director-general/speeches/detail/who-director-genera....
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. doi: 10.1001/jama.2020.2648. - DOI - PubMed
    1. Guangdi L, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Nat Rev Drug Discov. 2020;19(3):149–150. doi: 10.1038/d41573-020-00016-0. - DOI - PubMed